Contract Sterilization for EtO and Gamma: Industry Landscape
Terminal sterilization is a regulatory requirement for most medical devices and many pharmaceutical products. Ethylene oxide (EtO) and gamma irradiation remain the two dominant modalities, together accounting for over 80% of all contract sterilization volume globally. The contract sterilization market reached approximately USD 5.8 billion in 2025 and is projected to surpass USD 8 billion by 2029.
EtO vs. Gamma: Choosing the Right Modality
| Factor | Ethylene Oxide (EtO) | Gamma Irradiation |
|---|---|---|
| Mechanism | Chemical alkylation of DNA | Ionizing radiation (Co-60) |
| Temperature | 37–63 °C | Ambient |
| Material compatibility | Broad; preferred for moisture-sensitive products | Not suitable for some polymers (PTFE, acetal) |
| Cycle time | 12–72 hours (incl. aeration) | Minutes to hours |
| Residuals | EtO, ethylene chlorohydrin — aeration required | None |
| Regulatory scrutiny | High (EPA emissions regulations) | Moderate |
Major Contract Sterilization Providers
Sterigenics, part of Sotera Health, operates 48 facilities across 13 countries offering EtO, gamma, E-Beam, and X-Ray sterilization. STERIS AST (formerly Isomedix) runs over 50 contract sterilization and lab facilities globally with EtO, gamma, and E-Beam capabilities. Midwest Sterilization Corporation is the largest privately held EtO contract sterilizer in the U.S., operating from Jackson, MO and Laredo, TX.
Regulatory and Compliance Landscape
Contract sterilizers must comply with ISO 11135 (EtO sterilization) and ISO 11137 (radiation sterilization), along with FDA 21 CFR Part 820 for devices sold in the U.S. EPA emissions regulations for EtO have tightened significantly since 2020, driving facility upgrades and some plant closures. Buyers should verify a provider's compliance status with both health authority registrations and environmental permits.
Selection Criteria for Buyers
- Modality expertise
- Confirm validated processes for your specific product and packaging configuration
- Capacity and turnaround
- Many providers operate at high utilization — confirm available capacity and lead times before committing
- Geographic proximity
- Transportation costs and cold-chain requirements may favor regional providers
- Regulatory track record
- Review FDA warning letters, EPA compliance history, and audit outcomes